Kevin Hern: “If it is a bad policy, it is a bad policy next year, it is a bad policy two years later, it is just a bad policy.”

I will always advocate for those who are suffering from a rare disease and support efforts to bring treatments for these diseases to market.

One way to do this is by reducing the regulatory burden so that Title IV-B funding recipients can spend more time helping children and families, and less time waiting through the red tape.

It is sad that what we are dealing with is stifled innovation and a decrease in patient access due to the Inflation Reduction Act.

It is critical that we keep innovation here in the U.S., but it is also critical that we make sure healthcare is affordable.